 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper129th MAINE LEGISLATURE
FIRST REGULAR SESSION-2019
Legislative Document No. 1666
H.P. 1192 House of  Representatives,  April 30, 2019
An Act  To Require  Certain Health Care Providers To Provide 
Patients Detailed  Information  on the Risks Associated with the Use 
of Opioid Medications and Schedule II Drugs
(AFTER  DEADLINE)
Approved for  introduction by a majority  of the Legislative Council  pursuant to Joint Rule 
205.
Reference to the Committee on Health  Coverage, Insurance and Financial Services 
suggested and ordered printed.
ROBERT  B. HUNT
Clerk
Presented by Representative PICKETT of Dixfield.
Cosponsored by Senator FOLEY of  York and
Representatives: ANDREWS of  Paris, JAVNER of Chester, MADIGAN of Waterville, 
MORALES of South  Portland, MORRIS of Turner, PRESCOTT of Waterboro, TEPLER of 
Topsham, WARREN of Hallowell.

Page 1 - 129LR2257(01)-11Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  32 MRSA §2210, sub-§6, as enacted by PL 2017, c. 186, §1, is amended 
3to read:
46.  Opioid medication policy.  No later than January 1, 2018, a health care entity that 
5includes an individual licensed under this chapter whose scope of practice includes 
6prescribing opioid medication must have in place an opioid medication prescribing policy 
7that applies to all prescribers of opioid medications employed by the entity.  The policy 
8must include, but is not limited to, procedures and practices related to risk assessment, 
9informed consent and counseling on the risk of opioid use.  The policy must be consistent 
10with subsection 7.  For the purposes of this subsection, "health care entity" has the same 
11meaning as in Title 22, section 1718-B, subsection 1, paragraph B.
12Sec. 2.  32 MRSA §2210, sub-§7 is enacted to read:
137.  Opioid medication and schedule II drug information disclosure.  Prior to 
14issuing an initial prescription and prior to issuing a 3rd prescription after October 31, 
152019 of any opioid medication or a medication that is a schedule II drug to a patient, an 
16individual licensed under this chapter whose scope of practice includes prescribing opioid 
17medication or medication that is a schedule II drug shall inform the patient of the 
18following:
19A.  The risks associated with the use of the medication, specifically, that the 
20medication is highly addictive even when taken as prescribed, that there is a risk of 
21developing a physical or psychological dependence on the medication and that taking 
22more of the medication than prescribed or mixing sedatives, alcohol, benzodiazepines 
23or other central nervous system depressants with the medication can result in fatal 
24respiratory depression;
25B.  The reasons why the medication is necessary; and
26C.  Alternative treatments that may be available.
27The prescriber shall include a note in the patient's medical record that the prescriber has 
28discussed the information in this subsection with the patient or the patient's parent or legal 
29guardian if the patient is a minor.
30For the purposes of this subsection, "schedule II drug" has the same meaning as in the 
31federal Controlled Substances Act of 1970, 21 United States Code, Section 812.
32Sec. 3.  32 MRSA §2600-C, sub-§6, as enacted by PL 2017, c. 186, §2, is 
33amended to read:
346.  Opioid medication policy.  No later than January 1, 2018, a health care entity that 
35includes an individual licensed under this chapter whose scope of practice includes 
36prescribing opioid medication must have in place an opioid medication prescribing policy 
37that applies to all prescribers of opioid medications employed by the entity.  The policy 
38must include, but is not limited to, procedures and practices related to risk assessment, 
39informed consent and counseling on the risk of opioid use.  The policy must be consistent 
Page 2 - 129LR2257(01)-11with subsection 7.  For the purposes of this subsection, "health care entity" has the same 
2meaning as in Title 22, section 1718-B, subsection 1, paragraph B.
3Sec. 4.  32 MRSA §2600-C, sub-§7 is enacted to read:
47.  Opioid medication and schedule II drug information disclosure.  Prior to 
5issuing an initial prescription and prior to issuing a 3rd prescription after October 31, 
62019 of any opioid medication or a medication that is a schedule II drug to a patient, an 
7individual licensed under this chapter whose scope of practice includes prescribing opioid 
8medication or medication that is a schedule II drug shall inform the patient of the 
9following:
10A.  The risks associated with the use of the medication, specifically, that the 
11medication is highly addictive even when taken as prescribed, that there is a risk of 
12developing a physical or psychological dependence on the medication and that taking 
13more of the medication than prescribed or mixing sedatives, alcohol, benzodiazepines 
14or other central nervous system depressants with the medication can result in fatal 
15respiratory depression;
16B.  The reasons why the medication is necessary; and
17C.  Alternative treatments that may be available.
18The prescriber shall include a note in the patient's medical record that the prescriber has 
19discussed the information in this subsection with the patient or the patient's parent or legal 
20guardian if the patient is a minor.
21For the purposes of this subsection, "schedule II drug" has the same meaning as in the 
22federal Controlled Substances Act of 1970, 21 United States Code, Section 812.
23Sec. 5.  32 MRSA §3300-F, sub-§6, as enacted by PL 2017, c. 186, §3, is 
24amended to read:
256.  Opioid medication policy.  No later than January 1, 2018, a health care entity that 
26includes an individual licensed under this chapter whose scope of practice includes 
27prescribing opioid medication must have in place an opioid medication prescribing policy 
28that applies to all prescribers of opioid medications employed by the entity.  The policy 
29must include, but is not limited to, procedures and practices related to risk assessment, 
30informed consent and counseling on the risk of opioid use.  The policy must be consistent 
31with subsection 7.  For the purposes of this subsection, "health care entity" has the same 
32meaning as in Title 22, section 1718-B, subsection 1, paragraph B.
33Sec. 6.  32 MRSA §3300-F, sub-§7 is enacted to read:
347.  Opioid medication and schedule II drug information disclosure.  Prior to 
35issuing an initial prescription and prior to issuing a 3rd prescription after October 31, 
362019 of any opioid medication or a medication that is a schedule II drug to a patient, an 
37individual licensed under this chapter whose scope of practice includes prescribing opioid 
38medication or medication that is a schedule II drug shall inform the patient of the 
39following:
Page 3 - 129LR2257(01)-11A.  The risks associated with the use of the medication, specifically, that the 
2medication is highly addictive even when taken as prescribed, that there is a risk of 
3developing a physical or psychological dependence on the medication and that taking 
4more of the medication than prescribed or mixing sedatives, alcohol, benzodiazepines 
5or other central nervous system depressants with the medication can result in fatal 
6respiratory depression;
7B.  The reasons why the medication is necessary; and
8C.  Alternative treatments that may be available.
9The prescriber shall include a note in the patient's medical record that the prescriber has 
10discussed the information in this subsection with the patient or the patient's parent or legal 
11guardian if the patient is a minor.
12For the purposes of this subsection, "schedule II drug" has the same meaning as in the 
13federal Controlled Substances Act of 1970, 21 United States Code, Section 812.
14Sec. 7.  32 MRSA §3657, sub-§6, as enacted by PL 2017, c. 186, §4, is amended 
15to read:
166.  Opioid medication policy.  No later than January 1, 2018, a health care entity that 
17includes an individual licensed under this chapter whose scope of practice includes 
18prescribing opioid medication must have in place an opioid medication prescribing policy 
19that applies to all prescribers of opioid medications employed by the entity.  The policy 
20must include, but is not limited to, procedures and practices related to risk assessment, 
21informed consent and counseling on the risk of opioid use.  The policy must be consistent 
22with subsection 7.  For the purposes of this subsection, "health care entity" has the same 
23meaning as in Title 22, section 1718-B, subsection 1, paragraph B.
24Sec. 8.  32 MRSA §3657, sub-§7 is enacted to read:
257.  Opioid medication and schedule II drug information disclosure.  Prior to 
26issuing an initial prescription and prior to issuing a 3rd prescription after October 31, 
272019 of any opioid medication or a medication that is a schedule II drug to a patient, an 
28individual licensed under this chapter whose scope of practice includes prescribing opioid 
29medication or medication that is a schedule II drug shall inform the patient of the 
30following:
31A.  The risks associated with the use of the medication, specifically, that the 
32medication is highly addictive even when taken as prescribed, that there is a risk of 
33developing a physical or psychological dependence on the medication and that taking 
34more of the medication than prescribed or mixing sedatives, alcohol, benzodiazepines 
35or other central nervous system depressants with the medication can result in fatal 
36respiratory depression;
37B.  The reasons why the medication is necessary; and
38C.  Alternative treatments that may be available.
Page 4 - 129LR2257(01)-11The prescriber shall include a note in the patient's medical record that the prescriber has 
2discussed the information in this subsection with the patient or the patient's parent or legal 
3guardian if the patient is a minor.
4For the purposes of this subsection, "schedule II drug" has the same meaning as in the 
5federal Controlled Substances Act of 1970, 21 United States Code, Section 812.
6Sec. 9.  32 MRSA §18308, sub-§6, as enacted by PL 2017, c. 186, §5, is amended 
7to read:
86.  Opioid medication policy.  No later than January 1, 2018, a health care entity that 
9includes an individual licensed under this chapter whose scope of practice includes 
10prescribing opioid medication must have in place an opioid medication prescribing policy 
11that applies to all prescribers of opioid medications employed by the entity.  The policy 
12must include, but is not limited to, procedures and practices related to risk assessment, 
13informed consent and counseling on the risk of opioid use.  The policy must be consistent 
14with subsection 7.  For the purposes of this subsection, "health care entity" has the same 
15meaning as in Title 22, section 1718-B, subsection 1, paragraph B.
16Sec. 10.  32 MRSA §18308, sub-§7 is enacted to read:
177.  Opioid medication and schedule II drug information disclosure.  Prior to 
18issuing an initial prescription and prior to issuing a 3rd prescription after October 31, 
192019 of any opioid medication or a medication that is a schedule II drug to a patient, an 
20individual licensed under this chapter whose scope of practice includes prescribing opioid 
21medication or medication that is a schedule II drug shall inform the patient of the 
22following:
23A.  The risks associated with the use of the medication, specifically, that the 
24medication is highly addictive even when taken as prescribed, that there is a risk of 
25developing a physical or psychological dependence on the medication and that taking 
26more of the medication than prescribed or mixing sedatives, alcohol, benzodiazepines 
27or other central nervous system depressants with the medication can result in fatal 
28respiratory depression;
29B.  The reasons why the medication is necessary; and
30C.  Alternative treatments that may be available.
31The prescriber shall include a note in the patient's medical record that the prescriber has 
32discussed the information in this subsection with the patient or the patient's parent or legal 
33guardian if the patient is a minor.
34For the purposes of this subsection, "schedule II drug" has the same meaning as in the 
35federal Controlled Substances Act of 1970, 21 United States Code, Section 812.
36SUMMARY
37This bill requires a health care provider who is a prescriber of any opioid medication 
38or a medication that is a schedule II drug, before issuing an initial prescription and before 
39issuing a 3rd prescription of an opioid medication or a medication that is a schedule II 
Page 5 - 129LR2257(01)-11drug, to inform a patient of the risks of using the medication, the reason the medication is 
2necessary and alternative treatments that may be available.  It also requires the health care 
3provider to include a note in the patient's medical record that the health care provider 
4discussed the information with the patient.
